A major new study presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris has revealed a concerning link between GLP-1 receptor agonists, popular weight loss and diabetes medications, and a heightened risk of hair loss. The findings suggest that these drugs may trigger or expose underlying hair loss conditions rather than directly cause them.
Many patients taking Trulicity specifically have begun asking whether Trulicity can cause hair loss, and this new research suggests the concern is clinically valid.
What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists (GLP-1 RAs) like Ozempic, Wegovy, Saxenda, Trulicity, and Mounjaro are increasingly prescribed for managing type 2 diabetes and promoting weight loss. Their benefits for metabolic health and cardiovascular function are well-documented, but new research is shedding light on lesser-known side effects, including non-scarring hair loss.
Hair Loss Side Effects: What the Data Shows
The study, led by Yagiz Matthew Akiska from George Washington University, analysed data from over one million patients using the TriNetX US Collaborative Network. Researchers found that GLP-1 RA users had significantly higher rates of:
- Telogen Effluvium (TE) a form of temporary hair shedding associated with stress or hormonal changes
- Androgenic Alopecia (AGA) commonly known as male or female pattern baldness
- General Non-Scarring Hair Loss a broader category encompassing TE, AGA, and alopecia areata (AA), although AA itself showed no significant increase
These results were based on a matched cohort of 547,993 GLP-1 RA users and an equal number of non-users, adjusted for age, sex, BMI, race, and diabetes status.
Why This Matters
As GLP-1 medications become more widespread, unexpected side effects such as hair loss are attracting greater clinical attention. Akiska noted that most previous reports were anecdotal or based on small patient groups, making this large-scale analysis a significant step forward in understanding the true risks.
Participants included in the study had no prior history of hair loss or related conditions such as thyroid disease, chemotherapy, or nutritional deficiencies, which strengthens the case for a drug-related association.
Should You Be Concerned?
Whilst the findings do not prove that GLP-1 drugs directly cause hair loss, they highlight the need for greater awareness amongst patients and healthcare providers. If you are using GLP-1 medications and experiencing hair thinning or shedding, speak to your GP to explore possible causes and treatment options.
If you are taking Trulicity or any GLP-1 medication and noticing hair thinning, a specialist consultation can help identify the cause and the most appropriate non-surgical treatment for your needs.
Frequently Asked Questions
Q1. Does Trulicity directly cause permanent hair loss?
- Based on current evidence, Trulicity does not appear to cause permanent hair loss directly. The most commonly observed type, telogen effluvium, is typically reversible once the triggering stress has resolved. However, it may accelerate pattern hair loss in those who are genetically predisposed.
Q2. How soon after starting Trulicity can hair loss begin?
- Telogen effluvium typically appears two to four months after a physiological stressor. In this case, that stressor may be the onset of significant weight loss or the metabolic changes associated with starting a GLP-1 medication.
Q3. Is hair loss listed as a side effect of Trulicity?
- Hair loss is not prominently listed in Trulicity’s official prescribing information. However, based on the 2025 EADV study and growing patient reports, it is now an area of increasing clinical awareness.
Q4. What should I do if I notice hair thinning whilst on Trulicity?
- Do not stop your medication without speaking to your prescribing doctor first. Consult your GP to rule out other causes such as thyroid issues or nutritional deficiencies, and seek a specialist hair loss assessment to identify the type of hair loss and the most suitable treatment.
